[Sep 22, 2021] RAC-US PDF Dumps is essential on your RAC-US Exam Questions Certain Success!
RAC-US PDF Questions - Perfect Prospect To Go With RAC-US Practice Exam
NEW QUESTION 22
Which of the following is the BEST approach for mitigating potential regulatory compliance issues at your company?
- A. Train all new employees on regulatory compliance processes and assign a mentor to them.
- B. Document any failure to follow regulatory compliance processes in employee performance reviews.
- C. Develop documented procedures for regulatory compliance processes and train personnel.
- D. Train employees on all regulatory compliance processes using state-of-the-art systems.
Answer: C
NEW QUESTION 23
A global company is developing a sophisticated implantable medical device that is coated with antibiotics and biologics to enhance its efficacy.
The product is marketed in Country X.
where it is regulated as a medical device.
The same product, without the antibiotics and biologics, is marketed as a medical device in Country Y.
The company is proposing to start marketing the coated device in Country Y.
Which regulatory approach should the company propose?
- A. Submit the product as a medical device in Country Y as the product is already marketed in Country X as a medical device.
- B. Submit the product for review as a pharmaceutical product in Country Y.
- C. Examine decisions made about similar products in Country Y to propose the classification of the product.
- D. Apply for review of the additional part of the product as a pharmaceutical product in Country
Answer: D
NEW QUESTION 24
The API used for an approved drug product conforms to international monograph specifications and local pharmacopeia; however, the international monograph specifications of the API will be changing soon. Which is the most appropriate action for the regulatory affairs professional to take FIRST?
- A. Confirm that the international monograph change is not related to local pharmacopeia.
- B. Analyze the impact of the international monograph change on the local pharmacopeia.
- C. Prepare the international monograph change submission first and then prepare the local change when required.
- D. Transfer the notice of the upcoming international monograph change to QA for further processing.
Answer: D
NEW QUESTION 25
During the review of a design dossier, the reviewer asks why the company has only carried out a top-down risk approach. The reviewer is referring to which of the following?
- A. Hazard and operability study
- B. Failure mode and effect analysis
- C. ISO 14971 risk analysis
- D. Fault tree analysis
Answer: C
NEW QUESTION 26
In the process of obtaining a product approval, a regulatory affairs professional discovers that the product does not meet one of the specific technical requirements of the regulation.
However, competitors with substantially similar products have claimed compliance with the requirement and received approval. Which action should the regulatory affairs professional take FIRST?
- A. Notify senior management that the product cannot be registered.
- B. Inform the regulatory authority that such a requirement is not applicable to the product.
- C. Inform the internal departments to redesign the product to comply with this requirement.
- D. Discuss with the regulatory apriority and attempt to reach an acceptable solution.
Answer: D
NEW QUESTION 27
As part of the regulatory strategy for companies intending to manufacture a psychotropic product, which of the following approvals should be received FIRST?
- A. Import license
- B. Product license
- C. Export license
- D. Site license
Answer: D
NEW QUESTION 28
During new drug development, a new impurity in the drug substance is detected at a level of 0.12%. The intended maximum daily dose Is less than 2 g/day, and the drug Is known generally not to be toxic.
What should be done in response to identifying the impurity?
- A. Perform both identification and non-clinical qualification studies concurrently.
- B. Perform an identification study, wait until the result is available, and then consider performing a non-clinical qualification study.
- C. Perform a non-clinical qualification study, wait until the result is available, and then consider performing an identification study.
- D. Perform either an identification study or a non-clinical qualification study.
Answer: B
NEW QUESTION 29
The regulatory authority contacts the regulatory affairs professional regarding a complaint about a drug produced by the company. A consumer reported to the regulatory authority that the tablets have a slightly different color and break easily.
Which of the following actions should the regulatory affairs professional take?
- A. Ask that the regulatory authority provide the batch number printed on the packaging of the affected product.
- B. Respond to the regulatory authority that the company will provide copies of the relevant
QC records for batch release. - C. Ask that the regulatory authority provide the actual product subject to the complaint.
- D. Respond to the regulatory authority that the product subject to the complaint is most likely a counterfeit product.
Answer: A
NEW QUESTION 30
A regulatory authority announces an inspection of a regulatory affairs professional's facility during a holiday season when most of the staff Is not available. What is the MOST practical approach to this dilemma?
- A. Arrange for an inspection without all intended personnel.
- B. Inform the authority that the time is not suitable and request a new time
- C. Negotiate with colleagues and the authority to find a better time.
- D. Insist that key personnel be available for the inspection.
Answer: C
NEW QUESTION 31
Which of the following changes to a drug product is MOST likely to be implemented without prior regulatory authority approval?
- A. Deleting an ingredient of the drug product
- B. Introducing a new analytical method
- C. Deleting a drug substance
- D. Strengthening a precaution to the product labeling
Answer: D
NEW QUESTION 32
According to the ICH guideline on GMP for API, to which of the following is the MOST stringent requirement applied?
- A. Isolation and purification
- B. Production of Intermediate(s)
- C. Introduction of the API starting material
- D. Physical processing and packaging
Answer: D
NEW QUESTION 33
After numerous failed attempts to decrease an identified risk in a medical device to an acceptable level, the medical device continues to have unacceptable risks. However, the development team wants to continue development. Which is the BEST recommendation to make in this situation?
- A. Discontinue the project.
- B. Add a warning in the IFU.
- C. Perform another risk-benefit analysis.
- D. Redesign the device.
Answer: D
NEW QUESTION 34
Following the introduction of a new regulation, an evaluation of the company's products by the regulatory affairs professional indicates that 60 percent do not comply with the regulation.
What should the regulatory affairs professional do FIRST to meet the new requirement?
- A. Request a permanent waiver from the new regulation.
- B. Prepare documents for the files.
- C. Contact the trade association for advice.
- D. Communicate with the relevant internal departments.
Answer: D
NEW QUESTION 35
Company X encounters challenges in the global life cycle management of its medical devices. Which of the following Is MOST appropriate for improving product life cycle management?
- A. Identify countries where special requirements exist during the product development phase.
- B. Initiate a global submission process after all submission data are finalized.
- C. Utilize the STED template to complete global requirements.
- D. Plan regulatory approval update meetings with senior management and stakeholders.
Answer: A
NEW QUESTION 36
According to the GHTF, which of the following is NOT an exemption rule when evaluating the decision to report an adverse event?
- A. Deficiency of a device found by the user prior to patient use
- B. Malfunction occurring before the end of service life of the medical device
- C. Malfunction protection operated correctly
- D. Adverse event caused by patient conditions
Answer: D
NEW QUESTION 37
One month prior to the anticipated approval date for your product, the marketing application that you submitted to a major regulatory authority has become the subject of an advisory committee meeting of experts convened by the regulatory authority. The advisory committee members unanimously vote not to approve your product because of a safety concern. Two days after the advisory committee meeting, the regulatory authority requests additional information to support the safety of your product. Assuming you have no additional data to provide, which of the following would be your MOST appropriate response to the regulatory authority's request?
- A. "We have no additional information to provide at this time, but we can perform an additional analysis for a specific safety concern, if necessary."
- B. "We disagree with the advisory committee's decision because the committee neglected the thorough safety analysis that we provided."
- C. "Given the advisory committee's unanimous decision, we know that the product will not be approved, and additional data will not make any difference."
- D. "We have no additional information to provide at this time because we have already provided everything needed to support our product's approval."
Answer: A
NEW QUESTION 38
......
RAC-US Exam with Accurate Regulatory Affairs Certification (RAC) US PDF Questions: https://www.passexamdumps.com/RAC-US-valid-exam-dumps.html
True RAPS Exam Extraordinary Practice For the RAC-US Exam: https://drive.google.com/open?id=1tHYsMjsNWPcCZEhalMDU5fj-SOvGvCzH
